The era of the immunoglobulin A Fc receptor Fcα RI; its function and potential as target in disease
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: Immunoglobulin A (IgA) is the most prevalent antibody at mucosal sites, and has an important role in defense by preventing invasion of pathogens. Traditionally, IgA has been thought of as a non‐inflammatory antibody that helps to maintain homeostasis in the mucosa. However, in the last decade it has become clear that IgA is a very potent stimulus to initiate pro‐inflammatory cellular processes, especially after triggering the IgA Fc receptor (Fcα RI) on neutrophils. It was furthermore described that Fcα RI acts as a regulator between anti‐ and pro‐inflammatory responses of IgA. Although neutrophil activation is beneficial in (mucosal) infections, abnormal or excessive IgA immune complexes can induce disproportionate neutrophil migration and in this way initiate a perpetuating neutrophil recruitment and activation loop, which will result in severe tissue damage. Increasing evidence on this process plays a detrimental role in several diseases, including autoimmune IgA blistering diseases, a subtype of rheumatoid arthritis and ulcerative colitis. Inhibiting Fcα RI‐mediated activation may dampen inflammation in these patients. This process also opens up the possibility of targeting Fcα RI in antibody immunotherapy of cancer. Thus, interfering with IgA‐mediated Fcα RI activation may represent an attractive novel therapeutic strategy for multiple maladies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unravelling the pathogenesis of inflammatory bowel disease
Xavier, R. J., & Podolsky, D. K. (2007) · Nature · doi:10.1038/nature06005 · Cited by 4,364
Kaser, A., Zeissig, S., & Blumberg, R. S. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101225 · Cited by 1,806
Immunoglobulin A Coating Identifies Colitogenic Bacteria in Inflammatory Bowel Disease
Palm, N. W., de Zoete, M. R., Cullen, T. W., Barry, N. A., Stefanowski, J., Hao, L., Degnan, P. H., Hu, J., Peter, I., Zhang, W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.006 · Cited by 1,286
LANG, M. L., CHEN, Y.-W., SHEN, L., GAO, H., LANG, G. A., WADE, T. K., & WADE, W. F. (2002) · Biochemical Journal · doi:10.1042/bj20011696 · Cited by 60 · cited 12×
“Phosphorylated ITAMs subsequently act as docking platforms for a diverse repertoire of signaling molecules.”
BackgroundInfluential
Cited by
Tumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,023
B Cell Responses: Cell Interaction Dynamics and Decisions
Cyster, J. G., & Allen, C. D. C. (2019) · Cell · doi:10.1016/j.cell.2019.03.016 · Cited by 971
Neutrophils as emerging therapeutic targets
Németh, T., Sperandio, M., & Mócsai, A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0054-z · Cited by 653
New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura)
Heineke, M. H., Ballering, A. V., Jamin, A., Ben Mkaddem, S., Monteiro, R. C., & Van Egmond, M. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.10.009 · Cited by 329
Self-citationConsiderations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 302
Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease
van Erp, E. A., Luytjes, W., Ferwerda, G., & van Kasteren, P. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00548 · Cited by 281
IgA: Structure, Function, and Developability
de Sousa-Pereira, P., & Woof, J. M. (2019) · Antibodies · doi:10.3390/antib8040057 · Cited by 264
IgA subclasses have different effector functions associated with distinct glycosylation profiles
Steffen, U., Koeleman, C. A., Sokolova, M. V., Bang, H., Kleyer, A., Rech, J., Unterweger, H., Schicht, M., Garreis, F., Hahn, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13992-8 · Cited by 263
The inflammatory function of human IgA
Hansen, I. S., Baeten, D. L. P., & den Dunnen, J. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2976-8 · Cited by 170
Immunoglobulin A and liver diseases
Inamine, T., & Schnabl, B. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-017-1400-8 · Cited by 76
Hansen, I. S., Hoepel, W., Zaat, S. A. J., Baeten, D. L. P., & den Dunnen, J. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700883 · Cited by 69
“In addition to the protective role of IgA in host defense against pathogens, Abs of the IgA isotype are increasingly associated with various inflammatory disorders, including rheumatoid arthritis (RA), Sjögren’s syndrome, IgA nephropathy, alcoholic liver cirrhosis, and various skin-blistering diseases (10).”
Background
Metadata
- Authors
- Aleyd, E., Heineke, M. H., & van Egmond, M.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2015-10-26
- Volume
- 268
- Issue
- 1
- Pages
- 123-138
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2144077203
- Cited by
- 127
- References
- 4
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.